USE OF GLP-2 ANALOGUES IN PATIENTS WITH RENAL INSUFFICIENCY

The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KNUDSEN, Kim Mark, SONNE, Kim, AGERSNAP, Mikkel Askjær
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.